Effects of amphipathic drugs on L'[3H]glutamate binding to synaptic membranes and the purified binding protein. 1984

E K Michaelis, and C D Magruder, and R A Lampe, and N Galton, and H H Chang, and M L Michaelis

Four amphipathic molecules with known local anesthetic activity, dibucaine, tetracaine, chlorpomazine, and quinacrine, inhibited the binding of L-[3H]glutamic acid to rat brain synaptic plasma membranes and to the purified glutamate binding protein. Neither haloperidol nor diphenylhydantoin had significant inhibitory effects on the glutamate binding activity of the membranes or of the purified protein. The amphipathic drugs apparently inhibited L-[3H]glutamate binding to synaptic membranes by a mixed type of inhibition. The inhibitory activity of quinacrine on glutamate binding to the synaptic membranes was greater in a low ionic strength, Ca2+-free buffer medium, than in a physiologic medium (Krebs-Henseleit buffer). Removal of Ca2+ from the Krebs solution enhanced quinacrine's inhibition of glutamate binding. Quinacrine up to 1 mM concentration did not inhibit the high affinity Na+-dependent L-glutamate transport in these membrane preparations. The importance of Ca2+ in the expression of quinacrine's effects on the glutamate binding activity of synaptic membranes and the observed tetracaine and chlorpromazine-induced increases in the transition temperature for the glutamate binding process of these membranes, were indicative of an interaction of the local anesthetics with the lipid environment of the glutamate binding sites.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D011796 Quinacrine An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2. Mepacrine,Acrichine,Atabrine,Atebrin,Quinacrine Dihydrochloride,Quinacrine Dihydrochloride, Dihydrate,Quinacrine Dihyrochloride, (R)-Isomer,Quinacrine Dihyrochloride, (S)-Isomer,Quinacrine Dimesylate,Quinacrine Hydrochloride,Quinacrine Monoacetate,Quinacrine Monohydrochloride,Quinacrine Monomesylate,Quinacrine, (+-)-Isomer,Quinacrine, (R)-Isomer,Quinacrine, (S)-Isomer,Dihydrochloride, Quinacrine,Dimesylate, Quinacrine,Hydrochloride, Quinacrine,Monoacetate, Quinacrine,Monohydrochloride, Quinacrine,Monomesylate, Quinacrine
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D002746 Chlorpromazine The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. Aminazine,Chlorazine,Chlordelazine,Chlorpromazine Hydrochloride,Contomin,Fenactil,Largactil,Propaphenin,Thorazine,Hydrochloride, Chlorpromazine
D003992 Dibucaine A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) Cincain,Cinchocaine,Nupercainal,Nupercaine,Sovcaine
D005971 Glutamates Derivatives of GLUTAMIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the 2-aminopentanedioic acid structure. Glutamic Acid Derivatives,Glutamic Acids,Glutaminic Acids
D000779 Anesthetics, Local Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. Anesthetics, Conduction-Blocking,Conduction-Blocking Anesthetics,Local Anesthetic,Anesthetics, Topical,Anesthetic, Local,Anesthetics, Conduction Blocking,Conduction Blocking Anesthetics,Local Anesthetics,Topical Anesthetics
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

E K Michaelis, and C D Magruder, and R A Lampe, and N Galton, and H H Chang, and M L Michaelis
August 1980, Brain research,
E K Michaelis, and C D Magruder, and R A Lampe, and N Galton, and H H Chang, and M L Michaelis
January 1980, European journal of pharmacology,
E K Michaelis, and C D Magruder, and R A Lampe, and N Galton, and H H Chang, and M L Michaelis
July 1991, Brain research,
E K Michaelis, and C D Magruder, and R A Lampe, and N Galton, and H H Chang, and M L Michaelis
May 1981, Brain research,
E K Michaelis, and C D Magruder, and R A Lampe, and N Galton, and H H Chang, and M L Michaelis
January 1981, Neuroscience,
E K Michaelis, and C D Magruder, and R A Lampe, and N Galton, and H H Chang, and M L Michaelis
April 1982, Journal of neurochemistry,
E K Michaelis, and C D Magruder, and R A Lampe, and N Galton, and H H Chang, and M L Michaelis
February 1980, Biochemical Society transactions,
E K Michaelis, and C D Magruder, and R A Lampe, and N Galton, and H H Chang, and M L Michaelis
December 2001, Neurochemical research,
E K Michaelis, and C D Magruder, and R A Lampe, and N Galton, and H H Chang, and M L Michaelis
January 1984, Biokhimiia (Moscow, Russia),
E K Michaelis, and C D Magruder, and R A Lampe, and N Galton, and H H Chang, and M L Michaelis
August 1983, Journal of neurochemistry,
Copied contents to your clipboard!